SEC Filing Summary: Genmab A/S (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Genmab A/S, a foreign private issuer, for the month of June 2026. The report, dated June 29, 2026, incorporates by reference a Company Announcement (Exhibit 99.1) into the registrant's existing Form S-8 registration statements.
Key Financial Metrics
The provided filing text does not contain specific financial data. No values for revenue, profit, cash flow, margins, debt, or liquidity are disclosed in this document.
Material Changes
The filing text does not provide information regarding material changes versus prior comparable periods.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, risks, contingencies, or details on unusual items. The document serves primarily as a cover sheet to incorporate the referenced Company Announcement.
Investor Verification Checklist
- Review the full text of the Company Announcement dated June 29, 2026 (Exhibit 99.1), as the specific details of the report are contained therein rather than in this cover document.
- Verify the impact of the announcement on Genmab A/S's existing Form S-8 registration statements.
- Confirm the identity of the authorized signatory, Anthony Pagano, Executive Vice President & Chief Financial Officer.